Summary

US Early Toxicity Testing Market is valued at approximately USD 376.62 million in 2023 and is anticipated to grow with a healthy growth rate of more than 9.10% over the forecast period 2024-2032. Early toxicity testing constitutes a pivotal stage in the drug development continuum, serving to evaluate the potential adverse effects of novel compounds or substances on living organisms. This initial assessment aids in the identification of safety concerns and guides subsequent research and development endeavors. Early toxicity testing allows researchers to proactively manage risks and refine the safety characteristics of potential pharmaceuticals before progressing to later stages of development. In the US Early Toxicity Testing Market, Contract Research Organizations (CROs) assume a significant role in fostering industry expansion. They provide outsourced research services to pharmaceutical and biotechnology enterprises, addressing their need for toxicity testing as an integral component of drug development initiatives.

The escalating prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders has amplified the demand for new and effective treatments, necessitating extensive toxicological testing to ensure their safety, thus propelling growth in the US Early Toxicity Testing Market. Additionally, the expansion of the biotechnology and pharmaceutical sectors in the US has heightened the need for early toxicity testing services to support drug development endeavors, further driving market expansion. The United States holds a leading role in this industry, due to its robust economy's active participation in a significant range of drugs undergoing research and development. As of 2022, Pharma projects data reports that there are 10,736 drugs currently in progress, highlighting the nation's strong presence in the market.. However, the considerable costs associated with early toxicity testing, particularly for comprehensive studies involving diverse organisms and multiple endpoints, pose a significant barrier, particularly for smaller companies with limited financial resources. Moreover, stringent regulatory requirements imposed by agencies such as the US FDA and the European Medicines Agency extend the approval process for new drugs, potentially hindering market growth due to delayed market entry.

Major market player included in this report are:
Agilent Technologies Inc.
Bio-Rad Laboratories Inc.
Bruker Corporation
Charles River Laboratories International Inc.
Danaher Corporation
Enzo Biochem Inc.
PerkinElmer Inc.
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Technique
In Vivo
In Vitro
In Silico

By Toxicity Endpoint
Genotoxicity
Dermal Toxicity
Skin Toxicity
Ocular Toxicity
Phototoxicity
Others

By End Use
Pharmaceutical Industry
Cosmetic Industry
Chemical Industry
Food Industry
Others

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. US Early Toxicity Testing Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. US Early Toxicity Testing Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Technique
2.2.2. By Toxicity Endpoint
2.2.3. By End Use
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
Chapter 3. US Early Toxicity Testing Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. US Early Toxicity Testing Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. US Early Toxicity Testing Market Size & Forecasts by Technique 2022-2032
5.1. In Vivo
5.2. In Vitro
5.3. In Silico
Chapter 6. US Early Toxicity Testing Market Size & Forecasts by Toxicity Endpoint 2022-2032
6.1. Genotoxicity
6.2. Dermal Toxicity
6.3. Skin Toxicity
6.4. Ocular Toxicity
6.5. Phototoxicity
6.6. Others
Chapter 7. US Early Toxicity Testing Market Size & Forecasts by End Use 2022-2032
7.1. Pharmaceutical Industry
7.2. Cosmetic Industry
7.3. Chemical Industry
7.4. Food Industry
7.5. Others
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Agilent Technologies Inc.
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Bio-Rad Laboratories Inc.
8.3.3. Bruker Corporation
8.3.4. Charles River Laboratories International Inc.
8.3.5. Danaher Corporation
8.3.6. Enzo Biochem Inc.
8.3.7. PerkinElmer Inc.
8.3.8. Company 8
8.3.9. Company 9
8.3.10. Company 10
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes